AKT1 and colorectal carcinoma: This mutation is observed as a risk factor for CRC patients treated with AKT inhibitors, implying that the oncogenic activation of the Wnt/β-catenin pathway correlates with resistance mechanisms for inhibitors targeting the PI3K-AKT pathways [19].